Removing fibroids can prevent recurrent miscarriage

Article

Surgical removal of fibroids that distort the uterine cavity reduced the risk of second-trimester miscarriage to zero in a new study that also found solid evidence linking fibroids to recurrent miscarriage (ie, 3 or more consecutive miscarriages). MORE

Surgical removal of fibroids that distort the uterine cavity reduced the risk of second-trimester miscarriage to zero in a new study that also found solid evidence linking fibroids to recurrent miscarriage (ie, 3 or more consecutive miscarriages).

The study, which was published online September 28 in Human Reproduction, analyzed retrospective and prospective data from 966 women referred to a recurrent miscarriage clinic in Sheffield, United Kingdom. Researchers diagnosed fibroids in 79 women using combined transvaginal ultrasound and hysterosalpingography and removed uterine cavity-distorting (submucosal) fibroids from 25 women by hysteroscopy. Fifty-four women with nondistorting (intramural or subserosal) fibroids and a matched control group of 285 women with unexplained recurrent miscarriages had no intervention. Among the 25 women whose fibroids were removed, subsequent second-trimester miscarriage rates fell from 21.7% to 0%, (P<0.01) raising the live birth rate from 23.3% to 52%.

In addition, the study enabled researchers to calculate the prevalence of fibroids among women with recurrent miscarriages at 8.2% (79/966).

The 54 women with non-distorting fibroids achieved a live birth rate of 70.4% without intervention after referral to the clinic, compared with a 20.6% live birth rate before referral. The second-trimester miscarriage rate in this group dropped from 17.6% to 0%. These results were similar to results for the control group.

The researchers recommend offering hysteroscopic surgery to women with uterine-distorting fibroids who have suffered 1 or more second-trimester miscarriages but not to women with intramural or subserosal fibroids. A limitation of the study is lack of a control group for women who underwent surgery to remove fibroids, which precluded determining how the women would have fared without surgery.

Read other articles in this issue of Special Delivery.

Recent Videos
JoAnn Pinkerton discusses elinzanetant's crucial role in VMS therapy | Image Credit: uvahealth.com
Empowering women to take charge of their health | Image Credit: © piecesofi.com - © piecesofi.com - stock.adobe.com.
Supporting women through menopause with knowledge and care | Image Credit: © SHOTPRIME STUDIO - © SHOTPRIME STUDIO - stock.adobe.com.
How fezolinetant revolutionizes non-hormonal menopause therapy | Image Credit: imsociety.org
Gulf War exposures linked to early menopause in women veterans | Image Credit: linkedin.com.
Vanessa Muñiz discusses benefits of clinical hypnosis against hot flashes | Image Credit: mindbodymedicine.artsandsciences.baylor.edu
Elinzanetant displays positive phase 3 safety and efficacy data against VMS | Image Credit: © toeytoey - © toeytoey - stock.adobe.com.
© 2024 MJH Life Sciences

All rights reserved.